Diego Parente-Perez - Publications

Identification of non-actionable mutations with prognostic and predictive value in patients with advanced or metastatic non-small cell lung cancer.

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico

Published: September 05, 2023

Cost-effectiveness of atezolizumab versus pembrolizumab as first-line treatment in PD-L1-positive advanced non-small-cell lung cancer in Spain.

Journal: Cost effectiveness and resource allocation : C/E

Published: August 04, 2022

PD-L1 Inhibitors as Monotherapy for the First-Line Treatment of Non-Small-Cell Lung Cancer in PD-L1 Positive Patients: A Safety Data Network Meta-Analysis.

Journal: Journal of clinical medicine

Published: August 20, 2021

"High Tumor Burden" in Metastatic Non-Small Cell Lung Cancer: Defining the Concept.

Journal: Cancer management and research

Published: February 23, 2021

Practical Issues in the Use of Atezolizumab for Patients with Non-Small Cell Lung Cancer: Case Reports and Literature Review.

Journal: Oncology and therapy

Published: December 01, 2020

Prognostic factors for survival in patients with metastatic lung adenocarcinoma: An analysis of the SEER database.

Journal: Thoracic cancer

Published: July 20, 2020

PD-(L)1 Inhibitors in Combination with Chemotherapy as First-Line Treatment for Non-Small-Cell Lung Cancer: A Pairwise Meta-Analysis.

Journal: Journal of clinical medicine

Published: June 10, 2020

Economic impact of the resolution of drug related problems in an Emergency Department

Journal: Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria

Published: March 07, 2013